Shandong Weigao Group Medical Polymer Co (1066) AI Stock Analysis

• Market Cap: $26.18B
• Dividend Yield: 3.49%
• Average Volume (3M): 11.32M
• Price to Earnings (P/E): 11.7
• Beta (1Y): 1.01
• Revenue Growth: -3.09%
• EPS Growth: 0.67%
• Country: HK
• Employees: 12,719
• Sector: Healthcare
• Sector Strength: 54
• Industry: Medical - Instruments & Supplies
• EPS (TTM): 0.49
• Shares Outstanding: 4,522,332,000
• 10 Day Avg. Volume: 8,011,371
• 30 Day Avg. Volume: 11,324,577
• PEG Ratio: 17.43
• Price to Book (P/B): N/A
• Price to Sales (P/S): 0.00
• Price to Cash Flow (P/CF): 0.00
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: $5.20
• Price Target Upside: -11.84% Downside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 0

Shandong Weigao Group Medical Polymer Co has a solid financial foundation with strong profitability and stable financial position, though it faces challenges in revenue growth and cash flow management. The stock's technical indicators suggest positive momentum, and its valuation is attractive, offering a reasonable P/E ratio and a solid dividend yield. These factors contribute to a moderately strong overall stock score.

Shandong Weigao Group Medical Polymer Co Business Overview & Revenue Model

Company Description

Shandong Weigao Group Medical Polymer Co., Ltd. (1066) is a leading manufacturer and distributor of medical devices and consumables based in China. The company operates primarily in the healthcare sector, focusing on the production of a wide range of medical products, including single-use medical devices, orthopedic materials, and blood purification equipment. Shandong Weigao Group is committed to providing high-quality and cost-effective medical solutions to healthcare providers and institutions globally.

How the Company Makes Money

Shandong Weigao Group Medical Polymer Co. makes money through the manufacture and sale of a diverse portfolio of medical products. Its key revenue streams include single-use medical devices such as syringes, infusion sets, and blood bags. Additionally, the company generates income from its orthopedic materials and blood purification equipment segments. The company benefits from strategic partnerships and collaborations with healthcare institutions, which help to expand its market reach and product offerings. Revenue is also driven by its strong distribution network and its ability to innovate and meet the growing demand for medical products both domestically and internationally.

Shandong Weigao Group Medical Polymer Co Financial Statement Overview

Summary

Shandong Weigao Group Medical Polymer Co demonstrates strong profitability and a stable financial position, with healthy margins and conservative leverage. However, the slight decline in revenue and the lack of detailed cash flow data for the latest year suggest areas for improvement, particularly in cash flow management and revenue growth.

Income Statement

The company shows strong profitability with a consistent gross profit margin around 50% and a stable net profit margin in the range of 15-20%. However, there has been a slight decline in revenue growth, with a negative growth rate of approximately -1.1% from the previous year. EBIT and EBITDA margins remain healthy, indicating efficient cost management.

Balance Sheet

The balance sheet reflects a stable financial position. The debt-to-equity ratio is low, suggesting prudent leverage, while the equity ratio indicates a strong equity base with around 68% of total assets financed by equity. Return on Equity (ROE) has been relatively stable, reflecting decent returns to shareholders.

Cash Flow

The company has shown positive free cash flow, though the free cash flow growth rate is unavailable for the latest year. The operating cash flow to net income ratio is not calculable due to missing operating cash flow data for the latest year, indicating potential cash flow management issues that need addressing.

Breakdown
Dec 2023	Dec 2022	Dec 2021	Dec 2020	Dec 2019
Income Statement		Total Revenue
13.23B	13.62B	13.15B	11.35B	10.36B
	Gross Profit
6.64B	7.11B	7.27B	6.46B	6.51B
	EBIT
2.18B	3.56B	3.32B	2.61B	2.71B
	EBITDA
3.55B	4.38B	3.75B	3.30B	3.27B
	Net Income Common Stockholders
2.00B	2.76B	2.28B	2.09B	1.84B
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
7.33B	7.36B	7.06B	5.98B	4.66B
	Total Assets
33.67B	33.20B	30.37B	27.34B	26.33B
	Total Debt
4.17B	4.49B	4.14B	4.32B	5.52B
	Net Debt
-2.82B	-2.37B	-2.49B	-1.19B	1.28B
	Total Liabilities
9.68B	9.75B	9.46B	8.95B	9.33B
	Stockholders Equity
22.45B	21.67B	19.27B	17.55B	16.19B
Cash Flow		Free Cash Flow
2.11B	1.10B	1.92B	1.70B	1.34B
	Operating Cash Flow
2.80B	2.21B	3.04B	2.70B	2.32B
	Investing Cash Flow
-1.39B	-2.57B	-1.48B	423.22M	-1.34B
	Financing Cash Flow
-2.16B	-1.02B	-538.08M	-1.79B	-565.21M

Shandong Weigao Group Medical Polymer Co Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 5.90
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:1066, the sentiment is Positive. The current price of 5.9 is above the 20-day moving average (MA) of 5.69, above the 50-day MA of 5.51, and above the 200-day MA of 4.79, indicating a bullish trend. The MACD of 0.09 indicates Negative momentum. The RSI at 60.50 is Neutral, neither overbought nor oversold. The STOCH value of 73.05 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for HK:1066.

Shandong Weigao Group Medical Polymer Co Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
1093	76 Outperform	$66.04B	14.33	13.20%	5.99%	-9.60%	-27.18%
1513	74 Outperform	$30.26B	10.46	14.56%	5.68%	-5.37%	6.28%
1066	74 Outperform	$26.18B	11.73	8.95%	3.49%	-3.09%	0.67%
1179	68 Neutral	€83.42B	27.33	24.64%	4.79%	7.33%	-25.31%
2186	67 Neutral	HK$7.35B	14.34	3.53%	―	-3.12%	-12.71%
1177	66 Neutral	$68.53B	36.10	6.14%	1.56%	7.63%	-24.23%
Sector *	52 Neutral	$5.21B	3.55	-41.91%	2.83%	15.12%	0.42%

Shandong Weigao Group Medical Polymer Co Corporate Events

Shandong Weigao Group Makes Regulatory Announcement

Shandong Weigao Group Medical Polymer Company Limited has made an overseas regulatory announcement in compliance with the disclosure requirements of the Hong Kong Stock Exchange. The announcement, which was also published on the Shanghai Stock Exchange’s website, highlights the company’s adherence to regulatory standards, potentially impacting its market positioning and stakeholder confidence positively.

Shandong Weigao Announces AGM with Key Resolutions

Shandong Weigao Group Medical Polymer Company Limited has announced its upcoming annual general meeting (AGM) scheduled for May 27, 2025. The AGM will address various resolutions, including the approval of the company’s audited financial statements for 2024, the declaration of a final dividend, re-appointment of auditors, and re-election of directors and supervisors. Additionally, a special resolution will consider granting the board a general mandate to issue and deal with shares. These resolutions are crucial for the company’s governance and strategic planning, potentially impacting its market positioning and shareholder value.

Shandong Weigao Group Announces Regulatory Compliance Update

Shandong Weigao Group Medical Polymer Company Limited has made an overseas regulatory announcement in compliance with the disclosure requirements of the Hong Kong Stock Exchange. This announcement, published on the Shanghai Stock Exchange website, signifies the company’s adherence to regulatory standards and may impact its market positioning by enhancing transparency and investor confidence.

Shandong Weigao Group Announces Overseas Regulatory Update

Shandong Weigao Group Medical Polymer Company Limited has made an overseas regulatory announcement in compliance with the disclosure requirements of the Hong Kong Stock Exchange. This announcement, published on the Shanghai Stock Exchange website, is part of the company’s ongoing regulatory obligations, reflecting its commitment to transparency and adherence to market regulations.

Shandong Weigao Group Makes Overseas Regulatory Announcement

Shandong Weigao Group Medical Polymer Company Limited has made an overseas regulatory announcement in compliance with the disclosure requirements of the Hong Kong Stock Exchange. The announcement was also published on the Shanghai Stock Exchange’s website, indicating the company’s adherence to regulatory standards and its commitment to transparency in its operations.

Shandong Weigao Group Announces Final Dividend for 2024

Shandong Weigao Group Medical Polymer Co has announced a final cash dividend of RMB 0.1235 per share for the financial year ending December 31, 2024. This announcement reflects the company’s financial health and commitment to returning value to its shareholders, potentially impacting its market positioning positively.

Shandong Weigao Group Reports Increased Profit Amid Revenue Dip

Shandong Weigao Group Medical Polymer Company Limited reported a slight decrease in revenue for the year ended December 31, 2024, with a total of approximately RMB13.09 billion, down 1.1% from the previous year. However, the company achieved a 3.2% increase in net profit attributable to its owners, reaching approximately RMB2.07 billion. The directors have recommended a final dividend of RMB0.1235 per share, pending shareholder approval. This financial performance highlights the company’s resilience and potential for growth despite a challenging market environment.

Shandong Weigao Group Schedules Board Meeting for Annual Results and Dividend Decision

Shandong Weigao Group Medical Polymer Co. announced that its board of directors will meet on March 26, 2025, to review and approve the audited annual results for the year ending December 31, 2024. The meeting will also consider the potential declaration of a final dividend, which could impact shareholder returns and reflect the company’s financial health.

Shandong Weigao Announces Regulatory Compliance Update

Shandong Weigao Group Medical Polymer Company Limited has made an overseas regulatory announcement as per the disclosure requirements of the Hong Kong Stock Exchange. The announcement, published on the Shanghai Stock Exchange’s website, indicates compliance with local regulations and reflects the company’s ongoing commitment to transparency and regulatory adherence, which could impact its market positioning and stakeholder confidence.

Shandong Weigao Group Initiates H Share Repurchase to Enhance Company Value

Shandong Weigao Group Medical Polymer Company Limited announced its intention to repurchase H shares on the open market, a move aimed at preserving the company’s value. On February 11, 2025, the company completed its first share repurchase under the general mandate, acquiring 50,000 H shares at an average price of HKD4.62 each, totaling approximately HKD231,000. This strategic initiative reflects the company’s focus on optimizing shareholder value and market position while maintaining compliance with regulatory requirements.